[2026年02月] を試そう！リアルCCDM問題集で100%無料CCDM試験問題集
CCDMのPDF問題集試験問題 有効なCCDM問題集
質問 # 42
An international study collects lab values. Sites use different units in the source documents. Which of the following data collection strategies will have fewer transcription errors?
- A. Have all sites convert the values to the same unit system on the data collection form
- B. Allow values to be entered as they are in the source document and derive the units based on the magnitude of the value
- C. Allow values to be entered as they are in the source and the selection of units on the data collection form
- D. Use a structured field and print standard units on the data collection form
正解：C
解説：
In international or multicenter clinical studies, laboratory data often originate from different laboratories that use varying measurement units (e.g., mg/dL vs. mmol/L). The Good Clinical Data Management Practices (GCDMP, Chapter on CRF Design and Data Collection) provides clear guidance on managing this variability to ensure data consistency, traceability, and minimized transcription errors.
The approach that results in fewer transcription errors is to allow sites to enter lab values exactly as recorded in the source document (original lab report) and to require explicit selection of the corresponding unit from a predefined list on the data collection form or within the electronic data capture (EDC) system. This method (Option B) preserves the original source data integrity while enabling centralized or automated unit conversion later during data cleaning or statistical processing.
Option B also supports compliance with ICH E6 (R2) Good Clinical Practice (GCP), which mandates that transcribed data must remain consistent with the source documents. Attempting to derive units automatically (Option A) can lead to logical errors, while forcing sites to manually convert units (Option D) introduces unnecessary complexity and increases the risk of miscalculation or inconsistent conversions. Printing only standard units on the CRF (Option C) ignores local lab practices and can lead to discrepancies between CRF entries and source records, triggering numerous data queries.
The GCDMP emphasizes that CRF design must account for local variations in measurement systems and ensure that unit selection is structured (dropdowns, controlled lists) rather than free-text to prevent typographical errors and facilitate standardization during data transformation.
Therefore, Option B-"Allow values to be entered as they are in the source and the selection of units on the data collection form"-is the most compliant, accurate, and efficient strategy for minimizing transcription errors in international lab data collection.
Reference (CCDM-Verified Sources):
Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP), Chapter: CRF Design and Data Collection, Section 5.4 - Laboratory Data Management and Unit Handling ICH E6 (R2) Good Clinical Practice, Section 5.18 - Data Handling and Record Retention CDISC SDTM Implementation Guide, Section 6.3 - Handling of Laboratory Data and Standardized Units FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6 - Source Data and Accuracy of Data Entry
質問 # 43
A study is collecting ePRO assessments as well as activity-monitoring data from a wearable device. Which data should be collected from the ePRO and activity-monitoring devices to synchronize the device data with the visit data entered by the site?
- A. Study subject identifier
- B. Geo-spatial location and study subject identifier
- C. Geo-spatial location
- D. Study subject identifier and date/time
正解：D
解説：
To synchronize data from electronic patient-reported outcomes (ePRO) and wearable activity-monitoring devices with site-entered visit data, both the study subject identifier and date/time are essential.
According to the GCDMP (Chapter: Data Management Planning and Study Start-up), each dataset must contain key identifiers that allow for accurate data integration and temporal alignment. In studies involving multiple digital data sources, time-stamped subject identifiers are necessary to ensure that the device-generated data correspond to the correct subject and study visit.
The subject identifier ensures data traceability and linkage to the appropriate participant, while date/time allows synchronization of device data (e.g., activity or physiological measurements) with the corresponding site-reported visit or event. Geo-spatial data (options C and D) are typically not relevant to study endpoints and pose unnecessary privacy risks under HIPAA and GDPR guidelines.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Integration and eSource Data, Section 5.2 - Data Alignment and Synchronization Principles FDA Guidance for Industry: Use of Electronic Health Record Data in Clinical Investigations, Section 4.2 - Data Linking and Synchronization ICH E6 (R2) GCP, Section 5.5.3 - Data Traceability and Integrity
質問 # 44
In development of CRF Completion Guidelines (CCGs), which is a minimum requirement?
- A. CCGs must include a version control on the updated document
- B. CCGs must be signed before database closure to include all possible protocol changes affecting CRF completion
- C. CCGs are designed from the perspective of the Study Biostatistician to ensure that the data collected can be analyzed
- D. CCGs are developed with representatives of Data Management, Biostatistics, and Marketing departments
正解：A
解説：
Case Report Form Completion Guidelines (CCGs) are essential study documents that instruct site staff on how to complete each field of the CRF correctly. A minimum requirement for CCGs, according to Good Clinical Data Management Practices (GCDMP, Chapter: CRF Design and Data Collection), is that they must include version control.
Option A describes an important design consideration but not a minimum compliance requirement. Option B is inaccurate, as CCGs must be approved and implemented before data collection begins, not after. Option D includes an irrelevant stakeholder (Marketing).
Therefore, option C-"CCGs must include a version control on the updated document"-is correct and compliant with CCDM and GCP standards.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: CRF Design and Data Collection, Section 4.3 - Development and Maintenance of CRF Completion Guidelines ICH E6(R2) GCP, Section 8.2.1 - Essential Documents and Version Control Requirements
質問 # 45
A study takes body-composition measurements at baseline using a DEXA scanner. Which information is needed to correctly associate the body-composition data to the rest of the study data?
- A. Study number and subject number
- B. Subject number and visit number
- C. Study number and visit number
- D. Subject number
正解：B
解説：
To properly associate body-composition data (from a DEXA scanner) with other study data, both the subject number and the visit number are required.
According to the GCDMP (Chapter: Data Management Planning and Study Start-up), every clinical data record must be uniquely identifiable and linkable to a specific subject and study event. The subject number identifies the participant, while the visit number defines the temporal context in which the measurement was taken.
Without both identifiers, data integration becomes ambiguous-especially if multiple assessments occur over time (e.g., baseline, week 12, end of study). Including both ensures data traceability, integrity, and alignment with the protocol-defined schedule of events.
Study number (option A) alone does not distinguish between visits or subjects, and visit number alone (option C) lacks linkage to the individual participant.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Management Planning and Study Start-up, Section 4.4 - Data Linking and Identification Requirements ICH E6 (R2) GCP, Section 5.5.3 - Data Traceability Principles FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Data Identification Requirements
質問 # 46
The Medical Dictionary for Regulatory Activities (MedDRA) structure is in which of the following hierarchical orders, from most specific to least specific?
- A. LLT, PT, HLT, HLGT, SOC
- B. LLT, HLGT, PT, HLT, SOC
- C. LLT, PT, HLGT, HLT, SOC
- D. LLT, HLGT, HLT, PT, SOC
正解：A
解説：
The MedDRA (Medical Dictionary for Regulatory Activities) is a standardized medical terminology used for coding and analyzing adverse event (AE) and medical history data in clinical trials. Its hierarchical structure supports aggregation, analysis, and reporting across varying levels of medical specificity.
From most specific to least specific, the hierarchy is as follows:
Lowest Level Term (LLT): The most granular term, often reflecting the verbatim text reported by the investigator.
Preferred Term (PT): The standardized medical concept representing one or more LLTs describing the same condition.
High Level Term (HLT): A grouping of related PTs describing similar medical conditions.
High Level Group Term (HLGT): A broader grouping of related HLTs.
System Organ Class (SOC): The highest level of classification, grouping HLGTs by body system or etiology (e.g., cardiac disorders, infections).
Thus, the correct order - from most specific to least specific - is:
LLT → PT → HLT → HLGT → SOC, which corresponds to option D.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Medical Coding and Dictionaries, Section 5.2 - MedDRA Hierarchical Structure ICH M1 MedDRA Terminology Guide, Version 26.0 - Hierarchy Overview ICH E2B(R3) Guidelines - Clinical Safety Data Management
質問 # 47
What are the first logical specifications that need approval when building an efficient EDC database?
- A. eCRF Fields
- B. Edit Check Logic
- C. Metric Reports
- D. eCRF Guidelines
正解：A
解説：
In the EDC database build process, the first logical specifications that require approval are the electronic Case Report Form (eCRF) fields.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Database Design and Build), eCRF field specifications define what data elements are collected, their data types, permitted values, field lengths, and any associated metadata. Approval of these specifications forms the foundation for subsequent design components such as edit check programming, query management rules, and data validation logic.
Edit checks (B) are developed only after fields and structures are finalized.
Metric reports (C) and eCRF guidelines (D) are downstream documentation or tools, not logical specifications required at the build start.
Therefore, option A (eCRF fields) is correct, as their approval marks the first formal milestone in the EDC system development life cycle.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Design and Build, Section 4.2 - Logical Design and eCRF Field Specifications ICH E6(R2) GCP, Section 5.5.3 - System Design and Validation Documentation FDA 21 CFR Part 11 - System Validation and Documentation Controls
質問 # 48
If a data manager generated no additional manual queries on data in an EDC system and the data were deemed clean, why could the data appear to be not clean during the next review?
- A. The CRA can change the data during a quality review of source to database.
- B. The study coordinator can change the data due to re-review of the source.
- C. The medical monitor can override safety information entered in the system.
- D. The data manager may have accidentally changed the data.
正解：B
解説：
In an Electronic Data Capture (EDC) system, even after a data manager completes all manual queries and marks data as "clean," the data may later appear unclean if the site (study coordinator) makes subsequent updates in the system after re-reviewing the source documents.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Electronic Data Capture Systems), site users maintain the authority to modify data entries as long as the system remains open for data entry. The EDC system audit trail captures such changes, which can automatically invalidate prior data reviews, triggering new discrepancies or changing system edit-check statuses.
This situation commonly occurs when the site identifies corrections in the source (e.g., wrong date or lab result) and updates the EDC form accordingly. These post-cleaning changes require additional review cycles to ensure the database reflects accurate and verified information before final lock.
Options B, C, and D are incorrect - CRAs and medical monitors cannot directly change EDC data; they can only raise queries or request updates.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Electronic Data Capture Systems, Section 6.3 - Post-Cleaning Data Changes and Audit Trails ICH E6 (R2) GCP, Section 5.5.3 - Data Integrity and Change Control FDA 21 CFR Part 11 - Electronic Records: Change Documentation Requirements
質問 # 49
The Scope of Work would answer which of the following information needs?
- A. To look up the date of the next clinical monitoring visit for a specific site
- B. To look up which visit PK samples are taken
- C. To determine the number of data transfers budgeted for a project
- D. To find the name and contact information of a specific clinical data associate
正解：C
解説：
The Scope of Work (SOW) is a project management document that defines what services are included in the work agreement between the sponsor and the CRO or vendor. It outlines deliverables, responsibilities, timelines, and budget allocations.
According to the GCDMP (Chapter: Project Management in Data Management), the SOW includes specifications such as:
The number and frequency of data transfers,
Database build and lock milestones,
Quality control deliverables, and
Resource allocation for data management tasks.
The SOW does not cover operational site-level details such as monitoring schedules (B), protocol sampling details (C), or personnel contact lists (D).
Therefore, option A (number of data transfers budgeted for a project) correctly identifies a use case directly addressed in the SOW.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Project Management, Section 4.1 - Scope of Work and Resource Planning ICH E6(R2) GCP, Section 5.5 - Sponsor Oversight and Data Management Responsibilities PMI Project Management Framework - Scope Definition and Deliverable Specifications
質問 # 50
In a cross-functional team meeting, a monitor mentions performing source data verification (SDV) on daily diary data entered by patients on mobile devices. Which of the following is the best response?
- A. Diary data to be source data verified should be randomly selected
- B. Diary data to be source data verified should be selected using a risk-based approach
- C. All diary data should be source data verified
- D. The diary data should not be source data verified
正解：B
解説：
The best response is that diary data to be source data verified should be selected using a risk-based approach.
According to the GCDMP (Chapter: Data Quality Assurance and Control) and FDA Guidance on Risk-Based Monitoring (RBM), not all data require full SDV. Electronic patient-reported outcome (ePRO) or mobile diary data are typically direct electronic source data (eSource) captured at the time of entry, which already ensures authenticity and traceability.
A risk-based SDV approach focuses verification efforts on data critical to subject safety and primary efficacy endpoints, as defined in the study's Risk Assessment Plan or Monitoring Plan. Random or full verification of low-risk data (like diary compliance metrics) adds unnecessary effort and cost.
Thus, Option C aligns with current regulatory expectations and data management best practices.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 7.3 - Risk-Based Monitoring and SDV ICH E6 (R2) Good Clinical Practice, Section 5.18 - Risk-Based Quality Management FDA Guidance for Industry: Oversight of Clinical Investigations - A Risk-Based Approach to Monitoring (2013)
質問 # 51
Which is the best reason why front-end checks are usually kept minimal, when compared to back-end checks, in a paper-based clinical study?
- A. Data review can be performed at a later time due to the paper-based studies being smaller in size
- B. There is no need to alert the site personnel immediately about a data issue, as the study has happened already
- C. There are approvals required to raise a Data Clarification Form which could take time
- D. Data entry staff should be able to enter a value into the database just as it appears in the paper CRF
正解：D
解説：
In paper-based clinical studies, front-end data checks (those performed during data entry) are intentionally kept minimal to ensure that data are entered exactly as recorded on the paper CRF. This principle ensures data integrity by maintaining fidelity between source and electronic records before any cleaning or edit validation occurs.
The GCDMP (Chapter: Data Validation and Cleaning) explains that data entry operators should input values as written, even if they appear incorrect or inconsistent, because the purpose of front-end checks is not to interpret but to capture data faithfully. The back-end edit checks-performed later by data managers-are designed to identify inconsistencies, out-of-range values, or logical errors that require clarification through queries.
This approach separates data capture from data cleaning, minimizing bias and preserving original investigator input. Hence, option A accurately states the rationale for keeping front-end checks minimal in paper-based studies.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Validation and Cleaning, Section 4.2 - Data Entry, Edit Checks, and Query Process ICH E6(R2) GCP, Section 5.5.3 - Data Handling and System Controls FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.1 - Data Entry and Verification Processes
質問 # 52
In the EDC database, which factors are considered when defining user roles?
- A. Data Entry and Data Review
- B. Protocol Review and Data Entry
- C. Patient Recruitment and Protocol Review
- D. Data Review and Analysis Programming
正解：A
解説：
In Electronic Data Capture (EDC) systems, user roles are defined based on the functions and permissions required for specific study tasks. The most fundamental and universally applicable roles are Data Entry (performed by site staff) and Data Review (performed by monitors or data managers).
According to the GCDMP (Chapter: Technology and Electronic Data Capture Systems), defining user roles involves:
Assigning functional access levels (e.g., entry, review, query resolution).
Ensuring role-based security to protect data integrity.
Complying with 21 CFR Part 11 and ICH E6(R2) access control standards.
Options B, C, and D include functions (protocol review, analysis programming) not directly controlled within an EDC system.
Thus, option A (Data Entry and Data Review) correctly represents the two core factors considered when defining user roles.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Technology and Electronic Data Capture Systems, Section 4.3 - User Access, Roles, and Permissions ICH E6(R2) GCP, Section 5.5.3 - System Access and Security Controls FDA 21 CFR Part 11 - Access Control and Audit Trail Requirements
質問 # 53
Which information should an auditee expect prior to an audit?
- A. Audit plan or agenda
- B. Corrective action requests
- C. Auditor's credentials and certification number
- D. Standard operating procedures
正解：A
解説：
Prior to an audit, the auditee should expect to receive an audit plan or agenda, which outlines the scope, objectives, schedule, and logistics of the audit.
According to the GCDMP (Chapter: Quality Assurance and Audits), an audit plan ensures transparency, preparation, and efficient execution. It typically includes details such as:
The audit scope and objectives,
The audit team members,
Documents or processes to be reviewed, and
The audit schedule and timeframe.
This allows the auditee to prepare the necessary records, staff, and facilities. While the auditor's credentials (option A) may be shared informally, they are not a regulatory requirement. Corrective actions (option B) are outcomes of the audit, not pre-audit materials. Standard Operating Procedures (option C) may be requested during the audit but are not provided in advance.
Thus, Option D - Audit Plan or Agenda - is the correct and compliant answer.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Quality Assurance and Audits, Section 6.1 - Pre-Audit Planning and Communication ICH E6 (R2) Good Clinical Practice, Section 5.19.3 - Audit Procedures and Responsibilities FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Section 8.1 - Audit Preparation and Planning
質問 # 54
What is the purpose of providing the central laboratory vendor with a complete listing of subjects' demographic data?
- A. To assure that lab data for screening failure subjects have not been included in the lab data transmission
- B. To provide for an independent reconciliation of the patient and remote databases after database lock
- C. To assure that all subjects have lab data for valid visits
- D. To provide for an independent reconciliation of the patient and remote databases during study conduct
正解：D
解説：
Providing the central laboratory vendor with a complete subject demographic listing allows ongoing reconciliation between the sponsor's EDC system and the vendor's laboratory database during study conduct.
The GCDMP (Chapter: External Data Transfers and Integration) emphasizes that subject reconciliation ensures that all laboratory data correspond to valid enrolled subjects and visits. Regular reconciliation throughout the study prevents data mismatches, missing results, or misassigned lab reports.
This proactive measure supports timely query resolution and data integrity across systems. Waiting until after database lock (as in option A) would delay corrections and risk inconsistencies. Options B and D address secondary benefits but not the primary purpose-ongoing subject-level reconciliation.
Thus, option C is correct.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: External Data Transfers, Section 4.4 - Reconciliation and Vendor Communication ICH E6(R2) GCP, Section 5.5.3 - Data Management, Reconciliation, and Integration FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.3 - External Data Management
質問 # 55
Which is the MOST appropriate flow for EDC set-up and implementation?
- A. Protocol finalized, Database created, Edit Checks created, Database tested, Sites trained
- B. Database created, Subjects enrolled, Database tested, Sites trained, Database released
- C. Database created, Database tested, Sites trained, Protocol finalized, Database released
- D. CRF "wire-frames" created, CRFs reviewed, CRFs printed, CRFs distributed to sites
正解：A
解説：
The correct and compliant sequence for EDC system setup and implementation begins only after the study protocol is finalized, as all case report form (CRF) designs, database structures, and validation rules derive directly from the finalized protocol.
According to GCDMP (Chapter: EDC Systems Implementation), the proper order is:
Protocol finalized - defines endpoints and data requirements.
Database created - built according to the protocol and CRFs.
Edit checks created - programmed to validate data entry accuracy.
Database tested (UAT) - ensures functionality, integrity, and compliance.
Sites trained and system released - only then can data entry begin.
Option B follows this logical and regulatory-compliant sequence. Other options (A, C, D) are either paper-based workflows or violate GCP-compliant timelines (e.g., enrolling subjects before database validation).
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Electronic Data Capture (EDC) Systems, Section 5.2 - System Setup and Implementation Flow ICH E6(R2) GCP, Section 5.5.3 - Computerized Systems Validation and User Training Before Use FDA 21 CFR Part 11 - Validation and System Release Requirements
質問 # 56
A study is collecting pain levels three times a day. Which is the best way to collect the data?
- A. Sites calling patients daily and administering a pain questionnaire
- B. Using ePRO with reminders for data collection at each time point
- C. Study subjects calling into an IVRS three times a day to enter pain levels
- D. Using paper pain diary cards completed by study subjects
正解：B
解説：
The optimal method for collecting frequent patient-reported pain data is through electronic Patient-Reported Outcomes (ePRO) with built-in reminder functionality.
According to the GCDMP (Chapter: Electronic Data Capture Systems), ePRO systems provide a validated, real-time, and user-friendly interface for subjects to record time-sensitive data accurately. The use of automated reminders ensures compliance with protocol-specified data collection times, improving data completeness and accuracy.
Paper diaries (option A) are prone to recall bias and backfilling, while daily site calls (option B) are resource-intensive and introduce human error. IVRS systems (option C) are acceptable but less efficient and user-friendly than modern ePRO applications, which can integrate timestamp validation, compliance monitoring, and real-time alerts.
ePRO systems also comply with FDA 21 CFR Part 11 and ICH E6 (R2) for audit trails, authentication, and validation, making them the preferred solution for repeated PRO data collection.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Electronic Data Capture (EDC) Systems, Section 6.1 - Use of ePRO for Repeated Measures FDA Guidance for Industry: Electronic Source Data in Clinical Investigations, Section 5 - ePRO Compliance and Validation ICH E6 (R2) GCP, Section 5.5.3 - Electronic Data Systems and Recordkeeping
質問 # 57
In a physical therapy study, range of motion is assessed by a physical therapist at each site using a study-provided goniometer. Which is the most appropriate quality control method for the range of motion measurement?
- A. Programmed edit checks to detect out-of-range values upon data entry
- B. Independent assessment by a second physical therapist during the visit
- C. Comparison to the measurement from the previous visit
- D. Reviewing data listings for illogical changes in range of motion between visits
正解：B
解説：
In this scenario, the variable of interest-range of motion (ROM)-is a clinically measured, observer-dependent variable. The accuracy and reliability of such data depend primarily on the precision and consistency of the measurement technique, not merely on data entry validation. Therefore, the most appropriate quality control (QC) method is independent verification of the measurement by a second qualified assessor during the visit (Option D).
According to the Good Clinical Data Management Practices (GCDMP, Chapter on Data Quality Assurance and Control), quality control procedures must be tailored to the nature of the data. For clinically assessed variables, especially those involving human judgment (e.g., physical measurements, imaging assessments, or subjective scoring), real-time verification by an independent qualified assessor ensures that data are valid and reproducible at the point of collection. This approach directly addresses measurement bias, observer variability, and instrument misuse, which are primary sources of data error in clinical outcome assessments.
Other options, while valuable, address only data consistency or plausibility after collection:
Option A (comparison to previous visit) and Option C (reviewing data listings) are retrospective data reviews, suitable for identifying trends but not preventing measurement error.
Option B (programmed edit checks) detects only extreme or impossible values, not measurement inaccuracies due to technique or observer inconsistency.
The GCDMP and ICH E6 (R2) Good Clinical Practice guidelines emphasize that data quality assurance should begin at the source, through standardized procedures, instrument calibration, and dual assessments for observer-dependent measures. Having an independent second assessor ensures inter-rater reliability and provides direct confirmation that the recorded value reflects an accurate and valid measurement.
Reference (CCDM-Verified Sources):
Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 7.4 - Measurement Quality and Verification ICH E6 (R2) Good Clinical Practice, Section 2.13 - Quality Systems and Data Integrity FDA Guidance for Industry: Patient-Reported Outcome Measures and Clinical Outcome Assessment Data, Section 5.3 - Quality Control of Clinician-Assessed Data SCDM GCDMP Chapter: Source Data Verification and Quality Oversight Procedures
質問 # 58
An external organization has been hired to manage SAE follow-up for a large study. Which of the following would be used as guidance for exchange of the SAE data between the EDC system and the vendor's safety management system?
- A. Individual Case Safety Report
- B. Biomedical Research Domain Model
- C. Submission Data Tabulation Model
- D. Medical Document for Regulatory Activities
正解：A
解説：
The Individual Case Safety Report (ICSR) is the standard format used globally for the exchange of Serious Adverse Event (SAE) data between clinical data management systems (EDC) and safety management systems.
According to ICH E2B(R3) and Good Clinical Data Management Practices (GCDMP, Chapter: Safety Data Management and SAE Reconciliation), the ICSR provides the data structure and content standards for electronic transmission of safety data, including patient demographics, event details, outcomes, and product information. It ensures interoperability between systems by defining standardized message elements and controlled terminologies.
Other options are not applicable:
A . Medical Document for Regulatory Activities (MDRA) is not a recognized standard.
B . Biomedical Research Domain Model (BRIDG) provides conceptual modeling but not data exchange guidance.
D . SDTM is used for regulatory submission datasets, not real-time SAE exchange.
Thus, option C (Individual Case Safety Report) is correct, as it defines the internationally accepted electronic format for SAE data exchange between safety and clinical databases.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Safety Data Management and SAE Reconciliation, Section 4.3 - SAE Data Exchange and Standards ICH E2B(R3): Electronic Transmission of Individual Case Safety Reports FDA Guidance for Industry: Providing Regulatory Submissions in Electronic Format - Postmarketing ICSRs (2014)
質問 # 59
A statistician analyzes data from a randomized, double-blind, placebo-controlled study and finds that the placebo outperformed the investigational product. Which of the following is a plausible explanation for this?
- A. Sites appropriately dispensed the investigational product to the subjects.
- B. The treatment codes were incorrectly entered into the database.
- C. The investigational product performed well in this study population.
- D. The placebo was intended to contain medicinal properties.
正解：B
解説：
In a randomized, double-blind, placebo-controlled study, if statistical analysis shows that the placebo appears to outperform the investigational product, a likely cause is a data management or coding error, particularly in treatment code entry or mapping.
According to the GCDMP (Chapter: Database Design and Build), treatment assignment data - typically stored in randomization or code-break files - must be accurately integrated into the clinical database. Any mismatch between randomization codes, subject identifiers, or treatment arms can lead to incorrect grouping during analysis, producing false conclusions such as placebo superiority.
The Data Manager should initiate a root cause review of randomization data integration and treatment mapping. The placebo is never designed to have active medicinal effects (option A). Option D is incorrect because the described scenario implies a data inconsistency, not true efficacy differences. Proper verification of randomization coding and reconciliation between data management and statistical programming systems are essential.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Design and Build, Section 6.1 - Randomization and Treatment Code Management ICH E6 (R2) GCP, Section 5.5.3 - Data Verification and Coding Accuracy FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Data Mapping and Validation Requirements
質問 # 60
To ensure data quality and efficient integration of data, which of the following best describes the main topic that should be covered in initial discussions with a vendor providing the external data?
- A. Acceptable record, field, and file formats
- B. Metrics that will be used to measure data quality
- C. Criteria to trigger audits based on performance-monitoring reports
- D. Standard dictionary versioning and maintenance
正解：A
解説：
In initial vendor discussions for external data integration (e.g., central lab, ECG, imaging vendors), the most critical and foundational topic is defining the acceptable record, field, and file formats.
According to the GCDMP (Chapter: External Data Transfers and Integration), establishing the Data Transfer Specifications (DTS) early in the process ensures consistent structure, proper mapping, and compatibility between the vendor's system and the sponsor's database. These specifications define:
Data structure (variable names, formats, delimiters)
File naming conventions
Frequency of transfers
Methods of secure data transmission
Discussing formats first allows later alignment on data validation, quality metrics, and dictionary standards (which occur in subsequent stages). Without format agreement, all downstream processes risk misalignment, resulting in data incompatibility and rework.
Thus, option C (Acceptable record, field, and file formats) correctly represents the foundational focus of initial vendor discussions for ensuring data quality and integration efficiency.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: External Data Transfers and Integration, Section 4.1 - Data Transfer Planning and Specification Development ICH E6(R2) GCP, Section 5.5.3 - Data Handling and System Validation FDA Guidance: Computerized Systems Used in Clinical Investigations, Section 6.3 - Data Import and Format Control
質問 # 61
A study collects blood pressure. Which is the best way to collect the data?
- A. Check boxes for twenty-point increments
- B. High/Low radio button
- C. Coding a verbatim field with a MedDRA diagnosis
- D. Two continuous variables
正解：D
解説：
Blood pressure is a quantitative physiological measurement, typically consisting of two continuous numeric values: systolic and diastolic pressure. Therefore, the most appropriate and scientifically valid method of data collection is to use two continuous variables (e.g., systolic = 120 mmHg, diastolic = 80 mmHg).
According to the GCDMP (Chapter: CRF Design and Data Collection), data fields must be designed to capture the most precise, accurate, and analyzable form of clinical data. Numeric data should be collected using numeric data types to allow for range checks, calculations (e.g., mean arterial pressure), and statistical analysis.
Options such as categorical representations (radio buttons or check boxes) introduce rounding, data loss, and analytic limitations. Coding a verbatim diagnosis (option A) is inappropriate for numeric vital sign data and violates the principle of capturing data at the most granular level.
Thus, the correct and validated method per CCDM standards is two continuous variables, ensuring accuracy, traceability, and analytical flexibility.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: CRF Design and Data Collection, Section 4.2 - Best Practices for Quantitative Data Capture ICH E6 (R2) Good Clinical Practice, Section 5.5.3 - Data Accuracy and Collection Standards FDA Guidance for Industry: Electronic Source Data in Clinical Investigations, Section 4.3 - Data Format and Structure Requirements
質問 # 62
What are the key deliverables for User Acceptance Testing?
- A. Training
- B. Test Plan/Script/Results
- C. Project Plan
- D. eCRF Completion Guidelines
正解：B
解説：
The key deliverables for User Acceptance Testing (UAT) are the Test Plan, Test Scripts, and Test Results.
According to the GCDMP (Chapter: Database Design and Validation), UAT is the final validation step before a clinical database is released for production. It confirms that the system performs according to user requirements and protocol specifications.
The deliverables include:
UAT Test Plan: Defines testing objectives, scope, acceptance criteria, and responsibilities.
UAT Test Scripts: Provide step-by-step instructions for testing database functionality, edit checks, and workflows.
UAT Test Results: Document actual test outcomes versus expected outcomes, including any deviations and their resolutions.
These deliverables form part of the system validation documentation required under FDA 21 CFR Part 11 and ICH E6 (R2) to demonstrate that the database has been properly validated.
Project Plans (option A) and Training (option B) occur in earlier phases, while eCRF Completion Guidelines (option D) support site data entry, not system validation.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Design and Validation, Section 5.3 - User Acceptance Testing Deliverables FDA 21 CFR Part 11 - Validation Documentation Requirements ICH E6 (R2) Good Clinical Practice, Section 5.5.3 - System Validation Records
質問 # 63
An organization conducts over fifty studies per year. Currently each study is specified and set-up from scratch. Which of the following organizational infrastructure options would streamline database set-up and study-to-study consistency?
- A. Implementing controlled terminology for adverse events
- B. Improving the form or screen design process
- C. Adopting an ODM compliant database system
- D. Maintaining a library of form or screen modules
正解：D
解説：
To improve efficiency and ensure consistency across multiple studies, the most effective infrastructure solution is to maintain a centralized library of standardized forms or screen modules (e.g., CRF/eCRF templates).
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Database Design and Build), using a form library allows reuse of validated data collection modules for commonly collected domains such as demographics, adverse events, and vital signs. This reduces database setup time, enhances uniformity in data definitions, and ensures alignment with standards such as CDISC CDASH and SDTM.
While adopting ODM (A) provides standardized data exchange and interoperability, it does not inherently reduce setup workload. Improving design processes (C) enhances efficiency but doesn't guarantee consistency, and implementing controlled terminology (D) helps with coding standardization, not database structure.
Therefore, option B - maintaining a library of form or screen modules - provides the most direct and sustainable improvement for scalability and quality.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Design and Build, Section 5.3 - Use of Standard Libraries and Templates CDISC CDASH Implementation Guide, Section 3.2 - Reusable CRF Modules and Standardization ICH E6(R2) GCP, Section 5.5.3 - Standardization and Reuse in Data Collection Systems
質問 # 64
What is the main reason 21 CFR Part 11 requires that EDC systems maintain an audit trail?
- A. To preserve data availability
- B. To preserve source document verifications
- C. To preserve the ability for modifications
- D. To preserve data integrity
正解：D
解説：
The primary purpose of maintaining an audit trail as required under 21 CFR Part 11 is to preserve data integrity. According to the U.S. FDA's regulation on electronic records and signatures, every change to electronic data must be traceable, including information about who made the change, when it was made, and what the change entailed.
The Good Clinical Data Management Practices (GCDMP) outlines that an audit trail provides a permanent, chronological record of all modifications to clinical data. This ensures transparency and allows the reconstruction of the course of data entry and modification. The regulation aims to prevent unauthorized or undocumented data manipulation, thereby maintaining the accuracy, reliability, and validity of electronic records.
The FDA 21 CFR Part 11, Section 11.10(e) explicitly mandates that systems must use secure, computer-generated, time-stamped audit trails to independently record the date and time of operator entries and actions that create, modify, or delete electronic records. This ensures the data remains trustworthy and defensible in regulatory reviews or inspections.
Therefore, the main reason for requiring an audit trail is to preserve data integrity - ensuring that all data captured, modified, or transmitted is authentic, accurate, and complete throughout the study lifecycle.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Regulatory Compliance and Data Integrity FDA 21 CFR Part 11 - Electronic Records; Electronic Signatures, Section 11.10(e) ICH E6 (R2) Good Clinical Practice, Section 5.5.3 - Data Integrity and System Validation
質問 # 65
What should be done if the site continues to provide inconsistent data after several re-queries?
- A. Continue to re-query until the site changes the data
- B. Do nothing, the data will remain inconsistent
- C. Escalate the issue to the appropriate site contact personnel
- D. Gently lead the site to the correct response
正解：C
解説：
If a clinical site continues to provide inconsistent or illogical data after multiple queries, the correct course of action is to escalate the issue to the appropriate site contact personnel, typically the Clinical Research Associate (CRA) or Site Monitor.
According to the Good Clinical Data Management Practices (GCDMP), persistent data discrepancies often indicate a misunderstanding of the protocol, CRF instructions, or data entry procedures at the site level. Repeatedly re-querying the same data without escalation wastes time and risks introducing bias or error. By escalating through formal communication channels, the issue can be clarified through re-training, documentation review, or site monitoring visits.
The GCDMP emphasizes that escalation ensures data accuracy, site accountability, and protocol adherence, maintaining both data quality and regulatory compliance. Data managers must document the escalation process in the Data Management Plan (DMP) and ensure proper follow-up resolution is achieved.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Communication and Issue Escalation, Section 4.2 - Handling Persistent Data Discrepancies ICH E6 (R2) Good Clinical Practice, Section 5.18 - Monitoring and Site Communication FDA Guidance for Industry: Oversight of Clinical Investigations - Risk-Based Monitoring, Section on Issue Escalation
質問 # 66
A Data Manager receives an audit finding of three different instances of simultaneous log-ins to the EDC system by the same site user. This was observed at three different sites. Which of the following is the best long-term response to the audit finding?
- A. Acquiring technical controls from the same or a different system vendor that prevent simultaneous log-ins from the same user
- B. Requesting that the sites fire the offending users for a HIPAA violation and increasing the monitoring for the offending sites
- C. Removing all access to the system until the situation is resolved
- D. Refresher training for the offending users, re-communication of the binding nature of e-signatures to all users, routine monitoring for simultaneous log-ins from the same user
正解：D
解説：
The best long-term corrective and preventive action (CAPA) in this situation is a combination of user re-training, communication, and routine monitoring - as described in Option B.
According to the GCDMP (Chapter: Electronic Data Capture Systems) and FDA 21 CFR Part 11, user credentials and electronic signatures in clinical systems are legally binding and must be used only by the assigned individual. Simultaneous log-ins under the same credentials often indicate credential sharing, a compliance violation that must be addressed through user education, reinforced security policies, and ongoing system oversight.
While technical controls (option A) may be considered, behavioral and procedural reinforcement are the first lines of defense. Options C and D are excessive and not aligned with proportional CAPA practices.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Electronic Data Capture (EDC) Systems, Section 7.1 - User Access, Authentication, and Training FDA 21 CFR Part 11 - Electronic Records and Electronic Signatures, Sections 11.10(i) and 11.200(a) ICH E6 (R2) Good Clinical Practice, Section 5.5.3 - Access Control and Audit Trail Requirements
質問 # 67
......
SCDM CCDM 認定試験の出題範囲：
| トピック | 出題範囲 |
|---|---|
| トピック 1 |
|
| トピック 2 |
|
| トピック 3 |
|
| トピック 4 |
|
| トピック 5 |
|
究極のCCDM無料準備ガイド最新のSCDM練習テスト問題集：https://www.passtest.jp/SCDM/CCDM-shiken.html
今すぐゲットせよ！高評価SCDM CCDM試験問題集：https://drive.google.com/open?id=1G8YYph_ruoKC4xE_qXtpu3RJNNm6kDs5